Novartis India Buys Pfizer's Minipress for ₹1,250 Crore

Novartis India's board approved a ₹1,250 crore transaction to acquire the Minipress XL trademark from Pfizer Inc and Pfizer Products Inc. This deal, executed via an asset purchase agreement and trademark assignment deeds, marks a significant expansion of Novartis India's brand portfolio. Minipress XL, a medication containing prazosin for hypertension and benign prostatic hyperplasia symptoms, generated ₹228.6 crore in revenue in the 12 months concluding July 2026. The brand has demonstrated a 6.3 per cent compound annual growth rate over the past four years.

This strategic acquisition aligns with Novartis India's objective to grow through targeted brand purchases. The ₹1,250 crore acquisition represents approximately 5.5 times Minipress XL's annual revenue, based on recent financial data. This move follows a recent significant development where private equity firm ChrysCapital agreed in December 2025 to acquire a controlling stake in Novartis India, indicating a notable shift in the listed entity's ownership structure.